PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 16.5% in December

PainReform Ltd. (NASDAQ:PRFX) was the target of a large decline in short interest in December. As of December 15th, there was short interest totaling 121,809 shares, a decline of 16.5% from the November 30th total of 145,963 shares. Currently, 9.2% of the company’s stock are short sold. Based on an average trading volume of 217,670 shares, the days-to-cover ratio is currently 0.6 days. Based on an average trading volume of 217,670 shares, the days-to-cover ratio is currently 0.6 days. Currently, 9.2% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of research analysts have recently commented on PRFX shares. Wall Street Zen upgraded PainReform from a “strong sell” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

PainReform Price Performance

PainReform stock traded down $0.02 during mid-day trading on Wednesday, reaching $0.66. The stock had a trading volume of 42,536 shares, compared to its average volume of 1,440,690. PainReform has a one year low of $0.61 and a one year high of $6.65. The company has a 50-day moving average price of $0.98 and a two-hundred day moving average price of $1.28. The company has a market capitalization of $1.32 million, a price-to-earnings ratio of 0.00 and a beta of 0.56.

PainReform (NASDAQ:PRFX) last issued its earnings results on Wednesday, October 1st. The company reported ($0.55) earnings per share (EPS) for the quarter.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.